provided evidence of increased CD11b +/CD14 ϫ/CD15 +/CD33 + MDSC in the peripheral blood of NSCLC individuals, which played an essential role in mediating immunosuppression of NSCLC (46).Other authors recognized a unique subgroup of MDSCs in NSCLC patients, namely CD14 (+) S100A9 (+), which inhibited T cells through arginase, iNOS, and IL-13/IL-4Rα axis and were closely associated with adverse effects of chemotherapy (47). The gene discussed is S100A9; the disease is non-small cell lung carcinoma.